Aclaris Therapeutics, Inc. (ACRS) vs Puma Biotechnology, Inc. (PBYI)
- Aclaris Therapeutics, Inc. ACRS 3.28 −6.02%
- Puma Biotechnology, Inc. PBYI 9.83 −6.56%
Aclaris Therapeutics, Inc. and Puma Biotechnology, Inc. are both Biotechnology companies. Aclaris Therapeutics, Inc. and Puma Biotechnology, Inc. are of similar size ($543.0M and $513.7M). Aclaris Therapeutics, Inc. has negative trailing earnings, so its P/E is not meaningful; Puma Biotechnology, Inc. trades at 18.2×. Puma Biotechnology, Inc. grew revenue faster over the last twelve months: −2.86% against −51.0%. Puma Biotechnology, Inc. has the higher net margin (11.6% vs −921.5%) and the higher return on invested capital (42.6% vs −163.4%). Across the 17 metrics below, Puma Biotechnology, Inc. leads on 14 and Aclaris Therapeutics, Inc. on 3.
Valuation
Profitability
| Metric | ACRS | PBYI | Biotechnology median |
|---|---|---|---|
| Gross margin | 12.90% | 74.83% | 65.16% |
| Operating margin | (1,050.16%) | 13.16% | 0.00% |
| Net margin | (921.50%) | 11.55% | 0.00% |
| Free cash flow margin | (756.50%) | 17.79% | 0.00% |
| Return on equity | (59.10%) | 21.97% | (56.36%) |
| Return on assets | (41.07%) | 13.78% | (48.04%) |
| Return on invested capital | (163.35%) | 42.61% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack